The integration of Sequel's twiist automated insulin delivery system with Senseonics one-year CGM system is expected to give T1D patients more control over their diabetes care management. Image credit ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

People with type 2 diabetes (T2D) who began using continuous glucose monitoring (CGM) while receiving basal insulin had a 44% ...

A continuous glucose monitoring system marketed in Europe has, for the first time, been formally shown to satisfy a proposed ...

– Ascensia Diabetes Care has announced the U.S. launch of the Eversense® 365 continuous glucose monitoring (CGM) system, an advancement in diabetes management. – Developed by Senseonics Holdings, Inc.

Manage diabetes and not CGM interruptions with the new Eversense 365 CGM system – the only One Year CGM that is designed to help minimize device frustrations Ascensia launches the world’s first One ...

Credit: Ascensia Diabetes Care. Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management. The FDA has designated the Eversense 365 ...

The first fully implantable continuous glucose monitors can now be integrated with insulin pumps as part of an automated insulin delivery system As the first fully implantable device in the category, ...

The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...

PHC Holdings (OTCPK:PHCCF) and its subsidiary, Ascensia Diabetes Care, have signed a preliminary agreement to transfer the commercial operations for the Eversense Continuous Glucose Monitoring (CGM) ...

Sequel Med Tech and Senseonics have announced a collaboration to integrate Sequel’s twiist Automated Insulin Delivery (AID) System with Senseonics’ Eversense 365 one-year Continuous Glucose Monitoring ...

The FDA has issued a class two device recall for Senseonics’ Eversense continuous glucose monitoring system. This posting follows a September notice from the company that alerted providers and ...